Journal Article
. 2016 Feb; 20(10):xxiii-xxix, 1-201.
doi: 10.3310/hta20100.

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

Robert C Stein 1 Janet A Dunn 2 John M S Bartlett 3 Amy F Campbell 2 Andrea Marshall 2 Peter Hall 4 Leila Rooshenas 5 Adrienne Morgan 6 Christopher Poole 2 Sarah E Pinder 7 David A Cameron 8 Nigel Stallard 2 Jenny L Donovan 5 Christopher McCabe 9 Luke Hughes-Davies 10 Andreas Makris 11 OPTIMA Trial Management Group  
  • PMID: 26867046
  •     29 citations


Background: There is uncertainty about the chemotherapy sensitivity of some oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Multiparameter assays that measure the expression of several tumour genes simultaneously have been developed to guide the use of adjuvant chemotherapy for this breast cancer subtype. The assays provide prognostic information and have been claimed to predict chemotherapy sensitivity. There is a dearth of prospective validation studies. The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study (OPTIMA prelim) is the feasibility phase of a randomised controlled trial (RCT) designed to validate the use of multiparameter assay directed chemotherapy decisions in the NHS.

Objectives: OPTIMA prelim was designed to establish the acceptability to patients and clinicians of randomisation to test-driven treatment assignment compared with usual care and to select an assay for study in the main RCT.

Design: Partially blinded RCT with adaptive design.

Setting: Thirty-five UK hospitals.

Participants: Patients aged ≥ 40 years with surgically treated ER-positive HER2-negative primary breast cancer and with 1-9 involved axillary nodes, or, if node negative, a tumour at least 30 mm in diameter.

Interventions: Randomisation between two treatment options. Option 1 was standard care consisting of chemotherapy followed by endocrine therapy. In option 2, an Oncotype DX(®) test (Genomic Health Inc., Redwood City, CA, USA) performed on the resected tumour was used to assign patients either to standard care [if 'recurrence score' (RS) was > 25] or to endocrine therapy alone (if RS was ≤ 25). Patients allocated chemotherapy were blind to their randomisation.

Main Outcome Measures: The pre-specified success criteria were recruitment of 300 patients in no longer than 2 years and, for the final 150 patients, (1) an acceptance rate of at least 40%; (2) recruitment taking no longer than 6 months; and (3) chemotherapy starting within 6 weeks of consent in at least 85% of patients.

Results: Between September 2012 and 3 June 2014, 350 patients consented to join OPTIMA prelim and 313 were randomised; the final 150 patients were recruited in 6 months, of whom 92% assigned chemotherapy started treatment within 6 weeks. The acceptance rate for the 750 patients invited to participate was 47%. Twelve out of the 325 patients with data (3.7%, 95% confidence interval 1.7% to 5.8%) were deemed ineligible on central review of receptor status. Interviews with researchers and recordings of potential participant consultations made as part of the integral qualitative recruitment study provided insights into recruitment barriers and led to interventions designed to improve recruitment. Patient information was changed as the result of feedback from three patient focus groups. Additional multiparameter analysis was performed on 302 tumour samples. Although Oncotype DX, MammaPrint(®)/BluePrint(®) (Agendia Inc., Irvine, CA, USA), Prosigna(®) (NanoString Technologies Inc., Seattle, WA, USA), IHC4, IHC4 automated quantitative immunofluorescence (AQUA(®)) [NexCourse BreastTM (Genoptix Inc. Carlsbad, CA, USA)] and MammaTyper(®) (BioNTech Diagnostics GmbH, Mainz, Germany) categorised comparable numbers of tumours into low- or high-risk groups and/or equivalent molecular subtypes, there was only moderate agreement between tests at an individual tumour level (kappa ranges 0.33-0.60 and 0.39-0.55 for tests providing risks and subtypes, respectively). Health economics modelling showed the value of information to the NHS from further research into multiparameter testing is high irrespective of the test evaluated. Prosigna is currently the highest priority for further study.

Conclusions: OPTIMA prelim has achieved its aims of demonstrating that a large UK clinical trial of multiparameter assay-based selection of chemotherapy in hormone-sensitive early breast cancer is feasible. The economic analysis shows that a trial would be economically worthwhile for the NHS. Based on the outcome of the OPTIMA prelim, a large-scale RCT to evaluate the clinical effectiveness and cost-effectiveness of multiparameter assay-directed chemotherapy decisions in hormone-sensitive HER2-negative early breast would be appropriate to take place in the NHS.

Trial Registration: Current Controlled Trials ISRCTN42400492.

Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 10. See the NIHR Journals Library website for further project information. The Government of Ontario funded research at the Ontario Institute for Cancer Research. Robert C Stein received additional support from the NIHR University College London Hospitals Biomedical Research Centre.

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
John M S Bartlett, Jane Bayani, +18 authors, OPTIMA TMG.
J Natl Cancer Inst, 2016 May 01; 108(9). PMID: 27130929    Free PMC article.
Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI).
Jenny L Donovan, Leila Rooshenas, +7 authors, Jane M Blazeby.
Trials, 2016 Jun 10; 17(1). PMID: 27278130    Free PMC article.
Highly Cited.
Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.
S E Pinder, A F Campbell, +7 authors, R C Stein.
Br J Cancer, 2017 Feb 22; 116(7). PMID: 28222072    Free PMC article.
Accurate Measurement of Financial Toxicity Is a Prerequisite to Finding a Remedy.
Adam Martin, Peter S Hall.
Breast Care (Basel), 2017 Jun 01; 12(2). PMID: 28559762    Free PMC article.
Enabling recruitment success in bariatric surgical trials: pilot phase of the By-Band-Sleeve study.
S Paramasivan, C A Rogers, +11 authors, J L Donovan.
Int J Obes (Lond), 2017 Jul 04; 41(11). PMID: 28669987    Free PMC article.
Informed consent in randomised controlled trials: development and preliminary evaluation of a measure of Participatory and Informed Consent (PIC).
Julia Wade, Daisy Elliott, +17 authors, CSAW study group and ACST-2 study group.
Trials, 2017 Jul 19; 18(1). PMID: 28716064    Free PMC article.
Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
Alberto Peláez-García, Laura Yébenes, +9 authors, David Hardisson.
PLoS One, 2017 Sep 09; 12(9). PMID: 28886093    Free PMC article.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer.
Joseph A Sparano, Robert Gray, +13 authors, Joan Jones.
NPJ Breast Cancer, 2017 Nov 16; 3. PMID: 29138761    Free PMC article.
Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework.
Caroline Wilson, Leila Rooshenas, +13 authors, Jenny L Donovan.
Trials, 2018 Jan 21; 19(1). PMID: 29351790    Free PMC article.
The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests.
Alison F Smith, Mike Messenger, Peter Hall, Claire Hulme.
Pharmacoeconomics, 2018 Mar 05; 36(7). PMID: 29502176    Free PMC article.
Systematic Review.
Study protocol for VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a UK multicentre randomised controlled trial with an internal pilot (the VIOLET study).
Eric Lim, Tim Batchelor, +13 authors, VIOLET Trialists.
BMJ Open, 2019 Oct 17; 9(10). PMID: 31615795    Free PMC article.
One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit.
Christopher McCabe, Mike Paulden, +2 authors, Peter Hall.
Pharmacoeconomics, 2019 Dec 17; 38(2). PMID: 31840216    Free PMC article.
Pre-trial qualitative work with health care professionals to refine the design and delivery of a randomised controlled trial on kidney care.
Samantha Husbands, Fergus Caskey, +3 authors, Leila Rooshenas.
Trials, 2019 Apr 18; 20(1). PMID: 30992024    Free PMC article.
Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer.
Daisy Elliott, Freddie C Hamdy, +12 authors, Jenny L Donovan.
BJU Int, 2018 Jun 12; 122(6). PMID: 29888845    Free PMC article.
The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation.
Leila Rooshenas, Lauren J Scott, +21 authors, Romio feasibility study group.
J Clin Epidemiol, 2018 Oct 20; 106. PMID: 30339938    Free PMC article.
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Valerie E Crolley, Husam Marashi, +12 authors, Judy King.
Breast Cancer Res Treat, 2020 Mar 15; 180(3). PMID: 32170635    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Challenges Conveying Clinical Equipoise and Exploring Patient Treatment Preferences in an Oncology Trial Comparing Active Monitoring with Radiotherapy (ROAM/EORTC 1308).
Frances C Sherratt, Stephen L Brown, +5 authors, Bridget Young.
Oncologist, 2020 Feb 12; 25(4). PMID: 32045067    Free PMC article.
A census of pathway maps in cancer systems biology.
Brent M Kuenzi, Trey Ideker.
Nat Rev Cancer, 2020 Feb 19; 20(4). PMID: 32066900    Free PMC article.
Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer.
C Conefrey, J L Donovan, +18 authors, OPTIMA Prelim Study Group.
Clin Oncol (R Coll Radiol), 2020 Feb 25; 32(6). PMID: 32089356    Free PMC article.
The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer.
Rohit Bhargava, Beth Z Clark, +2 authors, David J Dabbs.
Mod Pathol, 2020 Mar 24; 33(8). PMID: 32203092    Free PMC article.
Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training.
John M S Bartlett, Jane Bayani, +8 authors, OPTIMA Trial Management Group.
PLoS One, 2020 Sep 04; 15(9). PMID: 32881987    Free PMC article.
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Helena Earl, Louise Hiller, +24 authors, Janet A Dunn.
Health Technol Assess, 2020 Sep 04; 24(40). PMID: 32880572    Free PMC article.
Cole Relaxation Frequency as a Prognostic Parameter for Breast Cancer.
William D Gregory, Shahila Mehboob Christie, +3 authors, Wendy Mikkelson.
J Patient Cent Res Rev, 2020 Nov 10; 7(4). PMID: 33163555    Free PMC article.
[Update of the German S3 breast cancer guideline : What is new for pathologists?]
A Lebeau, C Denkert, +2 authors, A Wöckel.
Pathologe, 2019 Mar 09; 40(2). PMID: 30847505
Maximising recruitment to a randomised controlled trial for chronic rhinosinusitis using qualitative research methods: the MACRO conversation study.
Clare McDermott, Jane Vennik, +7 authors, Claire Hopkins.
Trials, 2021 Jan 14; 22(1). PMID: 33436031    Free PMC article.
Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Maroun Bou Zerdan, Maryam Ibrahim, +2 authors, Hazem I Assi.
Front Oncol, 2021 Mar 06; 10. PMID: 33665165    Free PMC article.
Conservative treatment for uncomplicated appendicitis in children: the CONTRACT feasibility study, including feasibility RCT.
Nigel J Hall, Frances C Sherratt, +15 authors, Bridget Young.
Health Technol Assess, 2021 Feb 26; 25(10). PMID: 33630732    Free PMC article.